Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01664923 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 396
- Enrollment target
NCT01664923 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 396 participants.
The verdict
NCT01664923, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 396 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of enzalutamide vs bicalutamide in asymptomatic or mildly symptomatic patients with prostate cancer who have disease progression despite primary androgen deprivation therapy.
Interventions
- DRUG Enzalutamide
- DRUG Bicalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 2012-08 |
| Est. Completion | 2018-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01664923
The ClinicalTrials.gov registry entry for NCT01664923 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 396 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enzalutamide is the first listed.
NCT01664923 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01664923 about?
NCT01664923 is a clinical study titled "Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer". The purpose of this study is to determine the safety and efficacy of enzalutamide vs bicalutamide in asymptomatic or mildly symptomatic patients with prostate cancer who have disease progression despite primary androgen deprivation therapy.
What is the current status of trial NCT01664923?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 396 participants. The study started on 2012-08. Estimated completion is 2018-01.
What interventions are being tested in trial NCT01664923?
The interventions under investigation include: Enzalutamide (DRUG), Bicalutamide (DRUG).
Who is sponsoring clinical trial NCT01664923?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.